Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX 26 3-Year Share Buyback Ratio is -49.60 as of Dec. 2025. GuruFocus rates ASX:LDX with a GF Score™ of 26/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 614 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 89.9% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Lumos Diagnostics Holdings's current 3-Year Share Buyback Ratio was -49.60%.
The historical rank and industry rank for Lumos Diagnostics Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:LDX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -49.6 Med: -49.6 Max: -49.6
Current: -49.6
During the past 4 years, Lumos Diagnostics Holdings's highest 3-Year Share Buyback Ratio was -49.60%. The lowest was -49.60%. And the median was -49.60%.
ASX:LDX's 3-Year Share Buyback Ratio is ranked worse than 89.9% of 614
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs ASX:LDX: -49.60
Lumos Diagnostics Holdings (ASX:LDX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Lumos Diagnostics Holdings 3-Year Share Buyback Ratio Related Terms
ASX:LDX vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's 3-Year Share Buyback Ratio falls into.
Lumos Diagnostics Holdings 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -49.60 mean?
Lumos Diagnostics Holdings (ASX:LDX) has a 3-Year Share Buyback Ratio of -49.60 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Lumos Diagnostics Holdings and its competitors. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #552 out of 614 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is Lumos Diagnostics Holdings' 3-Year Share Buyback Ratio too high?
Lumos Diagnostics Holdings' current 3-Year Share Buyback Ratio is -49.60. Based on the distribution chart, Lumos Diagnostics Holdings ranks #552 out of 614 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #552 out of 614 companies for 3-Year Share Buyback Ratio. This places Lumos Diagnostics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current 3-Year Share Buyback Ratio is -49.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.12 — trading 475% above its estimated fair value. The current 3-Year Share Buyback Ratio is -49.60. Lumos Diagnostics Holdings' overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current 3-Year Share Buyback Ratio is -49.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.12 is trading 475% above its estimated GF Value™ of A$0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
3-Year Share Buyback Ratio: -49.60
GF Value™: A$0.02 vs. price of A$0.12 (475% above fair value)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
26GF Score
Get the complete analysis for ASX:LDX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
